摘要
他莫昔芬,为雌二醇竞争性拮抗剂,可以与乳腺细胞的雌激素受体(ER)结合,能有效地阻断雌激素的刺激作用。因此,他莫昔芬在临床上广泛用于治疗ER阳性乳腺癌患者。然而临床上他莫昔芬的耐药性成为乳腺癌治疗中的重要阻碍。miRNAs是一种内源性的非编码RNA,在肿瘤研究领域已成为一大热点,在肿瘤的发展和治疗中起着重要的作用。miRNA与他莫昔芬的耐药性密切相关。文章简述了miRNA在乳腺癌发生发展中的作用及其调节功能与他莫昔芬耐药性形成之间的关系。分析表明了miRNA在乳腺癌他莫昔芬耐药性中起着重要调节作用,并进一步证明了miRNA可以作为乳腺癌内分泌治疗敏感性的生物标志物。
Tamoxifen,a competitive estrogen receptor(ER)antagonist,can effectively block the stimulating effect of estrogen on tumor growth.Therefore,tamoxifen has been widely used for the treatment of ER-positive breast cancer.However,tamoxifen resistance represents a major challenge for treating breast cancer.miRNAs,a class of small non-coding RNAs,play an important role in tumor development and treatment and are closely related to tamoxifen resistance.The article briefly describes the role of miRNA in the occurrence and development of breast cancer and its relationship to tamoxifen resistance,suggesting that miRNAs play an important regulatory role in tamoxifen resistance and can be used as a biomarker for the sensitivity of endocrine therapy in breast cancer.
作者
刘琼晴(综述)
崔家骏(审校)
LIU Qiong-qing;CUI Jia-jun(College of Chemistry and Bioengineering,Yichun University,Yichun 336000,China;Translational Medical Center,Yichun University,Yichun 336000,China)
出处
《南昌大学学报（医学版）》
CAS
2019年第5期79-83,共5页
Journal of Nanchang University：Medical Sciences
基金
国家自然科学基金(31660325)
江西省高校落地计划科学前沿项目(93KJLD12093)
